These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33899544)

  • 1. Systemic analysis of the expression levels and prognosis of breast cancer-related cadherins.
    Xu M; Liu C; Pu L; Lai J; Li J; Ning Q; Liu X; Deng S
    Exp Biol Med (Maywood); 2021 Aug; 246(15):1706-1720. PubMed ID: 33899544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissection of the APCCdh1-Skp2 cascade in breast cancer.
    Fujita T; Liu W; Doihara H; Date H; Wan Y
    Clin Cancer Res; 2008 Apr; 14(7):1966-75. PubMed ID: 18381934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
    Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
    Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Biomarkers Associated With the Prognosis and Potential Pathogenesis of Breast Cancer via Integrated Bioinformatics Analysis.
    Wu M; Li Q; Wang H
    Technol Cancer Res Treat; 2021; 20():1533033821992081. PubMed ID: 33550915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
    Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
    Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
    Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
    Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors.
    Mao W; Zhou J; Hu J; Zhao K; Fu Z; Wang J; Mao K
    Front Public Health; 2022; 10():969070. PubMed ID: 36051999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-cadherin as prognostic factor for loco-regional relapse in breast cancer.
    Faria G; Cardoso MJ; Martins D; Bettencourt H; Amendoeira I; Schimitt F
    Acta Med Port; 2012; 25(2):97-105. PubMed ID: 22985920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of PLKs expression and prognosis in breast cancer.
    Jiawei W; Xiajun B; Tian S; Xuzheng G; Zhenwang Z
    Cancer Genet; 2022 Nov; 268-269():83-92. PubMed ID: 36206661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline.
    Zhu C; Feng X; Ye G; Huang T
    Medicine (Baltimore); 2017 Apr; 96(16):e6650. PubMed ID: 28422868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Fu XL; Li WP; Wang YH; Ma JG
    Oncotarget; 2016 May; 7(19):28384-92. PubMed ID: 27070091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of P-cadherin is an indicator of poor prognosis in breast cancer: a systematic review and meta-analysis.
    Sridhar S; Rajesh C; Jishnu PV; Jayaram P; Kabekkodu SP
    Breast Cancer Res Treat; 2020 Jan; 179(2):301-313. PubMed ID: 31664550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene signatures and prognostic analyses of the Tob/BTG pituitary tumor-transforming gene (PTTG) family in clinical breast cancer patients.
    Wu CC; Ekanem TI; Phan NN; Loan DTT; Hou SY; Lee KH; Wang CY
    Int J Med Sci; 2020; 17(18):3112-3124. PubMed ID: 33173433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of LCN1 as a Potential Biomarker for Breast Cancer by Bioinformatic Analysis.
    Yang Y; Li F; Luo X; Jia B; Zhao X; Liu B; Gao R; Yang L; Wei W; He J
    DNA Cell Biol; 2019 Oct; 38(10):1088-1099. PubMed ID: 31424267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of prognostic significance of cadherin (CDH) gene family in breast cancer.
    Ku SC; Liu HL; Su CY; Yeh IJ; Yen MC; Anuraga G; Ta HDK; Chiao CC; Xuan DTM; Prayugo FB; Wang WJ; Wang CY
    Aging (Albany NY); 2022 Oct; 14(20):8498-8567. PubMed ID: 36315446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the Expression of
    Chen C; Chen S; Pang L; Yan H; Luo M; Zhao Q; Lai J; Li H
    Biomed Res Int; 2020; 2020():6412593. PubMed ID: 32104702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased expression of CDH1 or CTNNB1 affects poor prognosis of patients with esophageal cancer.
    Ishiguro H; Wakasugi T; Terashita Y; Sakamoto N; Tanaka T; Mizoguchi K; Sagawa H; Okubo T; Takeyama H
    World J Surg Oncol; 2016 Sep; 14(1):240. PubMed ID: 27600761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
    Tang D; Xu S; Zhang Q; Zhao W
    Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome.
    Goyal A; Martin TA; Mansel RE; Jiang WG
    World J Surg Oncol; 2008 Jun; 6():56. PubMed ID: 18547424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.